292 related articles for article (PubMed ID: 27022417)
1. Preliminary Therapy Evaluation of (225)Ac-DOTA-c(RGDyK) Demonstrates that Cerenkov Radiation Derived from (225)Ac Daughter Decay Can Be Detected by Optical Imaging for In Vivo Tumor Visualization.
Pandya DN; Hantgan R; Budzevich MM; Kock ND; Morse DL; Batista I; Mintz A; Li KC; Wadas TJ
Theranostics; 2016; 6(5):698-709. PubMed ID: 27022417
[TBL] [Abstract][Full Text] [Related]
2. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
[TBL] [Abstract][Full Text] [Related]
3. Preparation and preclinical evaluation of (66)Ga-DOTA-E(c(RGDfK))2 as a potential theranostic radiopharmaceutical.
Lopez-Rodriguez V; Gaspar-Carcamo RE; Pedraza-Lopez M; Rojas-Calderon EL; Arteaga de Murphy C; Ferro-Flores G; Avila-Rodriguez MA
Nucl Med Biol; 2015 Feb; 42(2):109-14. PubMed ID: 25316595
[TBL] [Abstract][Full Text] [Related]
4. Cerenkov Luminescence Imaging for Radiation Dose Calculation of a ⁹⁰Y-Labeled Gastrin-Releasing Peptide Receptor Antagonist.
Lohrmann C; Zhang H; Thorek DL; Desai P; Zanzonico PB; O'Donoghue J; Irwin CP; Reiner T; Grimm J; Weber WA
J Nucl Med; 2015 May; 56(5):805-11. PubMed ID: 25840974
[TBL] [Abstract][Full Text] [Related]
5. Cerenkov luminescence imaging of medical isotopes.
Ruggiero A; Holland JP; Lewis JS; Grimm J
J Nucl Med; 2010 Jul; 51(7):1123-30. PubMed ID: 20554722
[TBL] [Abstract][Full Text] [Related]
6. Cerenkov luminescence imaging of αv β6 integrin expressing tumors using (90) Y-labeled peptides.
Satpati D; Hausner SH; Bauer N; Sutcliffe JL
J Labelled Comp Radiopharm; 2014 Jul; 57(9):558-65. PubMed ID: 25042833
[TBL] [Abstract][Full Text] [Related]
7. Two ⁹⁰Y-labeled multimeric RGD peptides RGD4 and 3PRGD2 for integrin targeted radionuclide therapy.
Liu Z; Shi J; Jia B; Yu Z; Liu Y; Zhao H; Li F; Tian J; Chen X; Liu S; Wang F
Mol Pharm; 2011 Apr; 8(2):591-9. PubMed ID: 21247151
[TBL] [Abstract][Full Text] [Related]
8. PET-Based Human Dosimetry of the Dimeric αvβ3 Integrin Ligand 68Ga-DOTA-E-[c(RGDfK)]2, a Potential Tracer for Imaging Tumor Angiogenesis.
López-Rodríguez V; Galindo-Sarco C; García-Pérez FO; Ferro-Flores G; Arrieta O; Ávila-Rodríguez MA
J Nucl Med; 2016 Mar; 57(3):404-9. PubMed ID: 26585063
[TBL] [Abstract][Full Text] [Related]
9. (64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression.
Li ZB; Cai W; Cao Q; Chen K; Wu Z; He L; Chen X
J Nucl Med; 2007 Jul; 48(7):1162-71. PubMed ID: 17574975
[TBL] [Abstract][Full Text] [Related]
10. Development of CD46 targeted alpha theranostics in prostate cancer using
Bobba KN; Bidkar AP; Wadhwa A; Meher N; Drona S; Sorlin AM; Bidlingmaier S; Zhang L; Wilson DM; Chan E; Greenland NY; Aggarwal R; VanBrocklin HF; He J; Chou J; Seo Y; Liu B; Flavell RR
Theranostics; 2024; 14(4):1344-1360. PubMed ID: 38389832
[No Abstract] [Full Text] [Related]
11. Anti-tumor effect of integrin targeted (177)Lu-3PRGD2 and combined therapy with Endostar.
Shi J; Fan D; Dong C; Liu H; Jia B; Zhao H; Jin X; Liu Z; Li F; Wang F
Theranostics; 2014; 4(3):256-66. PubMed ID: 24505234
[TBL] [Abstract][Full Text] [Related]
12. microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide.
Wu Y; Zhang X; Xiong Z; Cheng Z; Fisher DR; Liu S; Gambhir SS; Chen X
J Nucl Med; 2005 Oct; 46(10):1707-18. PubMed ID: 16204722
[TBL] [Abstract][Full Text] [Related]
13. Design and biological evaluation of ⁹⁹mTc-N₂S₂-Tat(49-57)-c(RGDyK): a hybrid radiopharmaceutical for tumors expressing α(v)β(3) integrins.
Ocampo-García BE; Santos-Cuevas CL; De León-Rodríguez LM; García-Becerra R; Ordaz-Rosado D; Luna-Guitiérrez MA; Jiménez-Mancilla NP; Romero-Piña ME; Ferro-Flores G
Nucl Med Biol; 2013 May; 40(4):481-7. PubMed ID: 23618768
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of an Anti-HER2 Nanobody Labeled with
Pruszynski M; D'Huyvetter M; Bruchertseifer F; Morgenstern A; Lahoutte T
Mol Pharm; 2018 Apr; 15(4):1457-1466. PubMed ID: 29502411
[TBL] [Abstract][Full Text] [Related]
15. Complementary, Selective PET Imaging of Integrin Subtypes α5β1 and αvβ3 Using 68Ga-Aquibeprin and 68Ga-Avebetrin.
Notni J; Steiger K; Hoffmann F; Reich D; Kapp TG; Rechenmacher F; Neubauer S; Kessler H; Wester HJ
J Nucl Med; 2016 Mar; 57(3):460-6. PubMed ID: 26635338
[TBL] [Abstract][Full Text] [Related]
16. Impact of bifunctional chelators on biological properties of 111In-labeled cyclic peptide RGD dimers.
Shi J; Kim YS; Chakraborty S; Zhou Y; Wang F; Liu S
Amino Acids; 2011 Nov; 41(5):1059-70. PubMed ID: 20052508
[TBL] [Abstract][Full Text] [Related]
17. (18) F labeled RGD-A7R peptide for dual integrin and VEGF-targeted tumor imaging in mice bearing U87MG tumors.
Ma Y; Liang S; Guo J; Guo R; Wang H
J Labelled Comp Radiopharm; 2014 Sep; 57(11):627-31. PubMed ID: 25294311
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of targeting α
Josefsson A; Cortez AG; Yu J; Majumdar S; Bhise A; Hobbs RF; Nedrow JR
Nucl Med Biol; 2024; 128-129():108880. PubMed ID: 38330637
[TBL] [Abstract][Full Text] [Related]
19. (68)Ga-labeled 3PRGD2 for dual PET and Cerenkov luminescence imaging of orthotopic human glioblastoma.
Fan D; Zhang X; Zhong L; Liu X; Sun Y; Zhao H; Jia B; Liu Z; Zhu Z; Shi J; Wang F
Bioconjug Chem; 2015 Jun; 26(6):1054-60. PubMed ID: 25853280
[TBL] [Abstract][Full Text] [Related]
20.
Li L; Rousseau J; Jaraquemada-Peláez MG; Wang X; Robertson A; Radchenko V; Schaffer P; Lin KS; Bénard F; Orvig C
Bioconjug Chem; 2021 Jul; 32(7):1348-1363. PubMed ID: 32216377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
